BMJ Open  
Medication adherence among allogeneic haematopoietic stem cell transplant recipients: a systematic review protocol

Chiara Visintini 1, Irene Mansutti 2, Alvisa Palese 1

ABSTRACT

Introduction Patients receiving a haematopoietic stem cell transplant (HSCT) are subjected to complex oral medications based on prophylactic and immunosuppressive treatments. Adherence to medication plays a role in survival, and medication non-adherence (MNA) is closely associated with graft-versus-host disease and other complications. The aim of this systematic review is to summarise the available evidence regarding prevalence rates of medication adherence, the risk factors of MNA, the effectiveness of interventions to increase medication adherence and the outcomes associated with MNA.

Methods and analysis We designed a systematic review according to the Joanna Briggs Institute methodology. We will search the Cochrane Library and the CINAHL, EMBASE, MEDLINE via PubMed, PsycINFO and Scopus databases. We will include published and unpublished primary studies: (a) on humans, from inception until 10 May 2022; (b) written in any language; (c) experimental (randomised and non-randomised), observational (prospective, retrospective cohort and case-control), correlational, cross-sectional and longitudinal; and (d) with a low risk of bias, according to the quality assessment we perform. We will exclude secondary and qualitative studies, protocols, publications without original data, including paediatrics or related to autologous HSCT. The primary outcome will be the prevalence of oral medication adherence; the secondary outcomes will be the risk factors of MNA, the interventions aimed at increasing medication adherence and the outcomes of MNA. Two researchers will independently screen the eligible studies, then extract and describe the data. Disagreements will be resolved by a third researcher. We will provide a qualitative narrative synthesis of the findings.

Ethics and dissemination Ethical approval is not required given that previously published studies will be used. We will disseminate the findings through conference presentations and publications in international peer-reviewed scientific journals.

PROSPERO registration number CRD4202215298.

INTRODUCTION

The number of haematopoietic stem cell transplants (HSCTs) is increasing worldwide, with 48512 transplants in the year 2019, including 19798 allogeneic transplants (41%) in Europe,1 and 23 768 HSCTs in the USA, of which 9498 (40%) were allogeneic.2 Patients who receive an HSCT must take a complex oral medication regimen based on prophylactic and immunosuppressive treatment.3–5 Thus, patients may encounter difficulties managing the high number of tablets, which may vary over time due to medication prescription changes.6 However, a high level of adherence to this very complex regimen is required to avoid infections and to minimise the risk of other complications, such as graft-versus-host disease (GvHD) or disease relapse.7 It is well known that adherence plays a key role during and after the HSCT, increasing survival, and medication non-adherence (MNA) is closely associated with GvHD.4, 6, 8, 9

Adherence is defined by WHO as ‘the extent to which the patient follows medical instructions.’10 It is composed of three phases: initiation (starting the prescribed medication intake), implementation (the agreement between a patient’s actual dosing compared with the medical prescription) and persistence (the length of time between
the first dose and last dose taken). Differently, the term ‘compliance’ implies patient passivity; therefore, the adherence concept and term was considered as a point of reference in this study.

The adherence rate in developed countries is about 50% among patients with chronic illness. To the best of our knowledge, the only systematic review available regarding medication adherence among recipients of an HSCT was published by Morrison and colleagues in 2017. Authors included five studies: two in adults, one in both children and adults, and two in paediatric population. The estimated adherence to oral therapy in that review was between 33% and 94.7% and it has been reported to decline over time among adults, except for Chieng et al, who reported an improvement in medication adherence over time. More recently, a prospective survey conducted by Ice and colleagues showed that out of 200 patients, 51% of them were not adherent to non-immunosuppressant medications, and 37.9% were not adherent to oral immunosuppressants. In a cross-sectional multicentric study enrolling 203 French adult recipients of an allogeneic HSCT, the MNA rate was 75%. In addition, in a secondary analysis of long-term survivors after an allogeneic HSCT, the authors reported an MNA prevalence rate of 68.7% to immunosuppressants.

Various methods have been used to assess medication adherence, which can be categorised into subjective, objective or biochemical measures. Among the first category, self-reported questionnaires (ie, the Compliance Evaluation Test, the modified Self-Efficacy for Appropriate Medication Use Scale, the Immunosuppressant Therapy Adherence Scale and the Morisky Medication Adherence Scale) have been used. Among the objective measures, the electronic Medication Administration Record and the prescription refill record have been adopted by researchers, while among biochemical measures, the serum drug-level measurements of immunosuppressants, alone or in combination, have been used. According to the available evidence, the use of self-report approaches combined with objective methods has been recommended to prevent heterogeneity in prevalence rates across studies. Moreover, it has been recommended to report when adherence is measured, the medications prescribed and the conceptual definition of adherence considered by researchers to increase the methodological quality of studies.

WHO has classified reasons for poor medication adherence in chronic illnesses into five categories: socioeconomic factors, health system/healthcare team-related factors, disease-related factors, therapy-related factors and patient-related factors. Among individuals who have undergone solid transplantation, several factors have been investigated regarding their association with MNA. At the patient-related level, some studies have documented the role of psychosocial factors by using the Stanford Integrated Psychosocial Assessment for Transplant (SIPAT) recipients, previously validated in the population who had received a solid organ transplant, and the Transplant Evaluation Rating Scale (TERS) as a pretransplant screening instrument to predict mortality, medication adherence and GvHD occurrence. Patient age, education, distress as well as the efficacy of the caregiver(s) have also been investigated. At the therapy-related level, the long-term duration of the therapy and the higher number of daily immunosuppressant pills have been studied. However, as has emerged from a published systematic review and recommended by the Patient-Centered Outcomes Working Group of the National Institutes of Health in 2015, future research is warranted to understand the facilitators and barriers of medication adherence.

Interventions to improve medication adherence have only been investigated to a limited extent, and to our best knowledge no summary of the available studies has been published. Specifically, a recent French retrospective study has assessed the effectiveness of pharmaceutical consultations on the adherence to oral immunosuppressive therapy. The intervention was performed by a hospital pharmacist to patients who had received an allogeneic HSCT (n=26) the day before discharge from the bone marrow transplantation centre (BMTC) and from 2 to 4 weeks after discharge. There were no significant findings in favour of the intervention group on medication adherence. In their quasi-experimental study, Polito et al compared medication counselling by a pharmacist and self-management with nursing supervision until discharge to a control group among 51 recipients of an allogeneic HSCT. There were no differences between the two groups regarding medication adherence, although at discharge the experimental group had higher median knowledge scores. Moreover, evidence regarding different educational strategies, such as peer education or the involvement of patients as trainers, has not yet been summarised.

The effects of medication adherence on clinical outcomes, such as infections, GvHD, disease relapse and mortality, are emerging in the literature. Mishkin et al reported no significant associations between SIPAT ratings and survival; however, patients with a high-risk SIPAT score had an increased risk of being admitted to the intensive care unit (ICU). Similarly, no differences emerged in survival between adherent and non-adherent patients in the prospective survey by Ice and colleagues, nor with respect to acute GvHD and infections in the quasi-experimental trial by Charra et al. On the other hand, there was a difference in the development of mild chronic GvHD among non-adherent patients compared with adherent patients. While pretransplant screening with the TERS has been documented to contribute to prediction of survival after HSCT, the TERS score did not correlate with the Medication Experience Scale for Immunosuppressants (MESI)—used as an adherence measure—suggesting that mortality is not associated with MNA. There is a need to summarise the evidence regarding clinical outcomes to discriminate between adherence and non-adherence behaviour and to identify patients at increased risk and in need of tailored interventions.
Studies regarding oral medication adherence prevalence, its associated factors, the effectiveness of interventions promoting it and the associated clinical outcomes among the adult recipients of an allogeneic HSCT are sparse and date back to recent years. Therefore, this review is intended to provide a comprehensive and quality-assessed summary of studies to inform clinical practice and to address further primary research. The findings will also increase the awareness of patients and their caregivers regarding MNA and its consequences, allowing them to act at any modifiable risk factors with targeted interventions. Our primary aim is to summarise the available evidence regarding the phenomenon of oral medication adherence among adult recipients of an allogeneic HSCT based on prevalence rates and data collection tools used to measure it. Our secondary aim is to summarise the evidence regarding the predictors and risk factors of MNA, the effectiveness of interventions to promote medication adherence and the clinical outcomes influenced by MNA, as documented in primary studies to date.

METHODS AND ANALYSIS
We have registered the present protocol in the International Prospective Register of Systematic Reviews (PROSPERO; registration number: CRD42022315298) on 8 April 2022. This protocol follows the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) (see online supplemental table 1). The review process will be completed within 6 months of protocol registration, and the systematic review will be reported following the updated PRISMA statement.28

Eligibility criteria
We will consider all primary studies to be eligible for the review, ensuring the following elements as defined with the Population, Intervention, Comparison and Outcomes and Time framework, as recommended by the Joanna Briggs Institute (JBI) methodology:29

► Population—adult (aged ≥18 years) patients who have undergone allogeneic or haploidentical HSCT and must take oral medication in the post-transplant phase, after discharge from BMTCs, regardless of the number of pills prescribed.

► Intervention—all kinds of interventions aimed at increasing medication adherence delivered from any healthcare providers (HCPs), during hospitalisation in the BMTCs and/or in the post-transplant phase, as an outpatient or remote follow-up.

► Comparison—usual care (ie, consultations, counseling, peer education and/or no comparison group).

► Outcome(s)—primary outcome describing the prevalence of oral medication adherence to immunosuppressant and non-immunosuppressant medications among the selected population after the discharge from BMTCs. The secondary outcomes are: (a) risk factors, barriers and predictors, and possibly related MNA assessment tools; (b) effectiveness of interventions aimed at increasing medication adherence; and (c) infections (bacterial, viral and fungal), acute and chronic GvHD, hospital readmission rate, disease relapse and overall survival, as associated with MNA.

► Time—from transplantation to 4 years post-HSCT, according to the longest median follow-up among the available studies.8

Inclusion and exclusion criteria
Our target population consists of adult patients who have undergone allogeneic or haploidentical HSCT, for any transplantation indications, and must take oral medications (both immunosuppressants and non-immunosuppressants, such as prophylactic medications) in the post-transplant phase.

We will include all published and unpublished primary studies: (a) on humans, from inception until 10 May 2022; (b) written in any language; (c) experimental (randomised and non-randomised), observational (prospective, retrospective cohort and case–control), correlational, cross-sectional and longitudinal, in addition to case series and case reports; and (d) with a low risk of bias, according to the quality assessment findings.29 Therefore, we will exclude secondary studies, qualitative studies, study protocols, case series and case reports and publications without original data (ie, comments, letters to the editor and editorials) or including the paediatric population (<18 years old) or relating to autologous HSCT. In addition, we will exclude studies where adherence does not relate to medication (ie, diet regimen, physical exercise).

Primary and secondary outcomes
The primary outcome of the review is the oral medication adherence rate. We will adopt the theoretical framework proposed by WHO,13 where adherence is defined as ‘the extent to which a person’s behaviour – taking medication, following a diet, and/or executing lifestyle changes, corresponds with agreed recommendations from a health care provider’. However, the focus of adherence will be the medication regimen, thus excluding ‘a diet, and/or executing lifestyle changes’ because they are not in line with our research aims. To measure the medication adherence rate, we will investigate subjective (ie, self-report questionnaires), objective (eg, prescription refill records) or biochemical measurements (serum drug levels).12

The secondary outcomes of this review are the following:

a. Risk factors, barriers or predictors of MNA as measured with tools.

b. Interventions increasing medication adherence (ie, full description, frequency of provision and duration, comparator).

c. Clinical outcomes as associated with MNA, such as the incidence rates of bacterial, viral and fungal infections; the incidence rates of acute and chronic GvHD; hospital and ICU readmission prevalence rates; disease relapse rates; and overall survival rates. We will assess
correlations or associations, if any, between medication adherence/MNA and patient-reported outcomes (ie, health-related quality of life, symptom experiences and patient satisfaction). 31

Information source
We will access the following databases: the Cochrane Library, Cumulative Index of Nursing and Allied Health Literature (CINAHL), EMBASE, MEDLINE via PubMed, PsycINFO and Scopus. An initial search in the PubMed database will be performed by the first researcher (CV) to identify keywords and Medical Subject Headings (MeSH) appropriate to the aims of the review. Then, the search strategy will be refined and tested by the other researchers (IM, AP). Thereafter, the search string will be inserted into the other databases.

We will also search for grey literature, including dissertation theses and reports, protocols or guidelines from international scientific societies regarding medication adherence in the HSCT population. We will screen the reference lists of the included articles and the excluded systematic reviews using a hand search, to identify additional sources. If the full text of a study is not available, we will contact the authors directly. In the case of studies written in languages other than English, Italian and German, all accessible by authors, we will employ native translators to provide an English translation.

Search strategy
Different search strings have been designed and applied, considering the primary outcome and the three secondary outcomes. The date of the last update of the literature search was 10 May 2022. The final search strategies for the six selected databases, with MeSH terms and keywords, are shown in online supplemental table 2. No filters and/or limits have been used.

Data management and selection process
We will download citations retrieved from the six electronic databases and import them into software (EndNote®) that will facilitate the study selection process, with automatic identification and exclusion of the duplicates.

After the removal of duplicates, the first researcher (CV) will screen article titles and abstracts according to the inclusion and exclusion criteria; then, another researcher (IM) will independently screen the articles, reaching a consensus by the third researcher (AP). Thereafter, the search string will be inserted into the other databases.

We will also search for grey literature, including dissertation theses and reports, protocols or guidelines from international scientific societies regarding medication adherence in the HSCT population. We will screen the reference lists of the included articles and the excluded systematic reviews using a hand search, to identify additional sources. If the full text of a study is not available, we will contact the authors directly. In the case of studies written in languages other than English, Italian and German, all accessible by authors, we will employ native translators to provide an English translation.

Data collection process
A pilot grid will be created in Microsoft Word® to extract data for at least 10% of the included articles, conducted independently by the first (CV) and second (IM) authors. After the pilot test, changes will be included if necessary, and the final chart will be developed, where study data will be reported and double-checked. Discrepancies in data extraction by the researchers will be discussed until a consensus is reached, with the supervision of a third researcher (AP).

An example of information that will be extracted from each study could be:

- Main characteristics (author(s), publication year, country, study design, study setting, study duration).
- Main and secondary study aims(s).
- Population profile, such as the number of participants, median age, gender distribution, race, ethnicity, socioeconomic status (where available), haematological disease due to HSCT, type of allogeneic HSCT, time from HSCT and name of oral medication(s), categorised into immunosuppressants or non-immunosuppressants.
- Main results of the study according to the primary and the secondary outcomes of the review:
  - Risk factors, predictors, barriers (description), by also describing the tools used to assess the risk of MNA.
  - Intervention(s) to improve medication adherence (description of the intervention, timing and provider(s) of the intervention(s), comparator).
  - Outcomes (ie, incidence rate of bacterial, viral and/or fungal infections, acute and/or chronic GvHD, hospital and/or ICU readmission rate, disease relapse rate and/or overall survival rate) and time from HSCT (in days) to assess them.

Risk of bias
We will perform a risk of bias assessment of all the individual studies included. The assessment will be performed independently by two researchers (CV, IM), and conflicts will be solved by a third researcher (AP).

The assessment will be based on the use of the JBI appraisal checklists, 39 according to the study design of the included studies. The JBI has different checklists for each study design (ie, randomised controlled trials, quasi-experimental, cohort). An example is the critical appraisal instrument for studies reporting prevalence data that will be used to assess the risk of bias of cross-sectional studies, which assesses the appropriateness of inclusion criteria (target population, sampling and sample size), the description of participants and the setting, the use of valid and reliable measurement of the studied condition, the use of appropriate statistical analysis and the assessment and management of adequate response rate. 32

There are four possible responses for each item: ‘yes’, ‘no’, ‘unclear’ or ‘not applicable’. The overall appraisal for each included study will consist of ‘seek further info’ or ‘include’ or ‘exclude’ the study from the final
inclusion. Therefore, studies assessed as excludable will not be considered in the data synthesis and a brief comment explaining the reason for the exclusion will be indicated. We will provide a table reporting the results of the risk of bias assessment for each included study.

**Data synthesis**

Two researchers (CV, IM) will independently summarise the findings, including only those studies considered eligible after the risk of bias assessment. First, the main study features will be summarised by reporting, for example, the origin country of the authors, the study aims and design, its duration, the sample size and the participants (ie, age, gender, ethnicity, education, type of HSCT). Then, a qualitative narrative synthesis of the results will be provided; specifically, the findings that emerge will be synthesised in four dimensions, according to the primary and the three secondary aims of this review. For example, the prevalence rates reported in the studies for immunosuppressant and non-immunosuppressant medications will be presented with the minimum, maximum and median values. The data collection methods, the description of risk factors of MNA and the interventions applied to improve adherence will also be summarised.

Regarding the investigated prevalence and outcomes, due to the expected different medication adherence measures and interventions across studies, the heterogeneity of the identified studies may prevent the ability to conduct a meta-analysis. However, if the data allow, two researchers (CV, IM) will independently investigate the heterogeneity of the studies using the $I^2$ statistic.

**Confidence in cumulative evidence**

We will assess the quality of the evidence by using the Grading of Recommendations Assessment, Development and Evaluation framework for both primary and secondary outcomes. ‘High’, ‘moderate’, ‘low’ and ‘very low’ are the levels that will be used to assess the strength and quality of the evidence regarding the identified outcomes. The evaluation will be performed independently by two researchers (CV, IM), and an expert researcher (AP) will resolve any disagreements.

**Patient and public involvement**

None.

**ETHICS AND DISSEMINATION**

Because the study will only be based on published and retrievable literature, no ethics approval is required. We will submit the findings of our systematic review to international peer-reviewed scientific journals based on the identified primary and secondary outcomes. Furthermore, we will disseminate a summary of the systematic review through professional meetings and conference presentations, to promote implementation in HCP practice, such as providing screening tools to recognise patients at risk, barriers and risk factors of MNA or interventions to improve medication adherence.

**DISCUSSION**

We aim to summarise the available studies regarding the phenomenon of oral medication adherence by means of prevalence rates, predictors and risk factors of MNA, the effectiveness of interventions to support it and outcomes associated with MNA among the HSCT population. Although we will employ a systematic approach and search an extensive number of databases, a publication bias might occur. Moreover, the expected heterogeneity across studies regarding their measures, tools and interventions might prevent a quantitative synthesis of the results. Furthermore, the external validity of the findings will be only for adult population: we decided to exclude the paediatric population because of the differences in psychological answers to the disease and medication posology and to the influence of the child–parent dyad on medication adherence. In addition, facilitators and barriers could be different between the paediatric and the adult population.

The findings will be of interest to various stakeholders, including HCPs (such as nurses, haematologists and psychologists working in BMTCs and in the follow-up setting), patients who have received an HSCT, their caregivers and their representatives. Although disease relapse remains the leading cause of mortality among patients after receiving an HSCT, a substantial improvement in survival and a reduction of complications have been reported over the years. Therefore, also considering the increase in the incidence of GvHD, medication adherence has become a priority in designing and delivering healthcare interventions during and after HSCT.

Complications and failure of transplant during hospitalisation have mostly been attributed to biological reasons. There has been a recent increase in attention towards medication adherence among patients who have received a transplant, especially in the case of early discharge and after, in the outpatient follow-up. Therefore, the findings will increase the information available to HCPs, patients, their caregivers and representatives in understanding the factors hindering or promoting medication adherence. Moreover, this review will inform HCPs regarding the most effective interventions capable of promoting medication adherence by considering all factors involved—from those related to the complexity of the therapy to the uncertainty and psychological distress experienced by the patients and their caregivers. Providing data on the phenomenon of medication adherence might increase the awareness of HCPs regarding the educational needs during hospitalisation and over time, because not all BMTCs have reference HCPs in charge of transitional care. Moreover, providing evidence might increase the opportunities to benchmark the data at each centre with that accumulated in the literature and appropriately summarised. Finally, the findings of this review may also
reveal possible gaps in the HSTC literature and highlight research questions to address with primary studies.

**Contributors** CV and AP conceptualised the protocol. CV wrote the protocol. IM and AP methodologically and critically revised the protocol. CV is the guarantor of the review. All authors have contributed, read and approved the final protocol.

**Funding** The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

**Competing interests** None declared.

**Patient and public involvement** Patients and/or the public were not involved in the design, conduct, or reporting, or dissemination plans of this research.

**Patient consent for publication** Not applicable.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Supplemental material** This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is permited others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is

**ORCID iDs** Chiara Visintini http://orcid.org/0000-0003-1174-741X
Alvisa Palese http://orcid.org/0000-0002-3508-844X

**REFERENCES**


**Supplementary table 1** Preferred Reporting Items for Systematic review and Meta-Analysis Protocols (PRISMA-P) checklist: recommended items to address in a systematic review protocol.\(^{27}\)

<table>
<thead>
<tr>
<th>Section/topic</th>
<th>#</th>
<th>Checklist item</th>
<th>Information reported</th>
<th>Section where item is reported</th>
</tr>
</thead>
<tbody>
<tr>
<td>ADMINISTRATIVE INFORMATION</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Title</td>
<td>1a</td>
<td>Identify the report as a protocol of a systematic review</td>
<td>Yes</td>
<td>Title</td>
</tr>
<tr>
<td>Identification</td>
<td>1b</td>
<td>If the protocol is for an update of a previous systematic review, identify as such</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>Registration</td>
<td>2</td>
<td>If registered, provide the name of the registry (such as PROSPERO) and registration number in the Abstract</td>
<td>Yes</td>
<td>Abstract and Methods and Analysis</td>
</tr>
<tr>
<td>Authors</td>
<td>3a</td>
<td>Provide name, institutional affiliation, e-mail address of all protocol authors; provide physical mailing address of corresponding author</td>
<td>Yes</td>
<td>First page</td>
</tr>
<tr>
<td>Contributions</td>
<td>3b</td>
<td>Describe contributions of protocol authors and identify the guarantor of the review</td>
<td>Yes</td>
<td>Author contribution</td>
</tr>
<tr>
<td>Amendments</td>
<td>4</td>
<td>If the protocol represents an amendment of a previously completed or published protocol, identify as such and list changes; otherwise, state plan for documenting important protocol amendments</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>Support</td>
<td>5a</td>
<td>Indicate sources of financial or other support for the review</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>Sponsor</td>
<td>5b</td>
<td>Provide name for the review funder and/or sponsor</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>Role of sponsor or funder</td>
<td>5c</td>
<td>Describe roles of funder(s), sponsor(s), and/or institution(s), if any, in developing the protocol</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>INTRODUCTION</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rationale</td>
<td>6</td>
<td>Describe the rationale for the review in the context of what is already known</td>
<td>Yes</td>
<td>Introduction</td>
</tr>
<tr>
<td>Objectives</td>
<td>7</td>
<td>Provide an explicit statement of the question(s) the review will address with reference to participants, interventions, comparators, and outcomes (PICO)</td>
<td>Yes</td>
<td>Eligibility criteria</td>
</tr>
<tr>
<td>METHODS</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eligibility criteria</td>
<td>8</td>
<td>Specify the study characteristics (such as PICO, study design, setting, time frame) and report characteristics (such as years considered, language, publication status) to be used as criteria for eligibility for the review</td>
<td>Yes</td>
<td>Inclusion and exclusion criteria</td>
</tr>
<tr>
<td>Information sources</td>
<td>9</td>
<td>Describe all intended information sources (such as electronic databases, contact with study authors, trial registers or other grey literature sources) with planned dates of coverage</td>
<td>Yes</td>
<td>Information sources</td>
</tr>
<tr>
<td>Search strategy</td>
<td>10</td>
<td>Present draft of search strategy to be used for at least one electronic database, including planned limits, such that it could be repeated</td>
<td>Yes</td>
<td>Search strategy</td>
</tr>
</tbody>
</table>

\(^{27}\) BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance on the supplemental material which has been supplied by the author(s). BMJ Open 2022; 12:e065676. doi: 10.1136/bmjopen-2022-065676
<table>
<thead>
<tr>
<th>Data management</th>
<th>11a</th>
<th>Describe the mechanism(s) that will be used to manage records and data throughout the review</th>
<th>Yes</th>
<th>Data management and selection process</th>
</tr>
</thead>
<tbody>
<tr>
<td>Selection process</td>
<td>11b</td>
<td>State the process that will be used for selecting studies (such as two independent reviewers) through each phase of the review (that is, screening, eligibility and inclusion in meta-analysis)</td>
<td>Yes</td>
<td>Data management and selection process</td>
</tr>
<tr>
<td>Data collection process</td>
<td>11c</td>
<td>Describe planned method of extracting data from reports (such as piloting forms, done independently, in duplicate), any processes for obtaining and confirming data from investigators</td>
<td>Yes</td>
<td>Data collection process</td>
</tr>
<tr>
<td>Data items</td>
<td>12</td>
<td>List and define all variables for which data will be sought (such as PICO items, funding sources), any pre-planned data assumptions and simplifications</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>Outcomes and prioritization</td>
<td>13</td>
<td>List and define all outcomes for which data will be sought, including prioritization of main and additional outcomes, with rationale</td>
<td>Yes</td>
<td>Primary and secondary outcomes</td>
</tr>
<tr>
<td>Risk of bias in individual studies</td>
<td>14</td>
<td>Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the outcome or study level, or both; state how this information will be used in data synthesis</td>
<td>Yes</td>
<td>Risk of bias</td>
</tr>
<tr>
<td>DATA Synthesis</td>
<td>15a</td>
<td>Describe criteria under which study data will be quantitatively synthesized</td>
<td>Yes</td>
<td>Data synthesis</td>
</tr>
<tr>
<td></td>
<td>15b</td>
<td>If data are appropriate for quantitative synthesis, describe planned summary measures, methods of handling data and methods of combining data from studies, including any planned exploration of consistency (such as $I^2$, Kendall’s $\tau$)</td>
<td>Yes</td>
<td>Data synthesis</td>
</tr>
<tr>
<td></td>
<td>15c</td>
<td>Describe any proposed additional analyses (such as sensitivity or subgroup analyses, meta-regression)</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td></td>
<td>15d</td>
<td>If quantitative synthesis is not appropriate, describe the type of summary planned</td>
<td>Yes</td>
<td>Data synthesis</td>
</tr>
<tr>
<td>Meta-bias(es)</td>
<td>16</td>
<td>Specify any planned assessment of meta-bias(es) (such as publication bias across studies, selective reporting within studies)</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>Confidence in cumulative evidence</td>
<td>17</td>
<td>Describe how the strength of the body of evidence will be assessed (such as GRADE)</td>
<td>Yes</td>
<td>Confidence in cumulative evidence</td>
</tr>
</tbody>
</table>

n, number.
### Supplementary table 2

Final search strategy for the six investigated databases (no limits and/or filters have been used).

<table>
<thead>
<tr>
<th>Database</th>
<th>String number</th>
<th>Researched outcome</th>
<th>Search strings</th>
</tr>
</thead>
</table>
| PUBMED      | #1            | Medication adherence/MNA                        | (“Hematopoietic Stem Cell Transplantation”[Mesh] OR “Transplantation, Homologous”[Mesh] OR stem cell transplant* OR bone marrow transplant* OR haematopoietic stem cell transplant* OR allogeneic transplant* OR haploididentical transplant* AND (“Medication Adherence”[Mesh] OR medication adherence OR medication nonadherence OR medication non-adherence OR medication non adherence OR Drug Adherence OR Medication Persistence OR medication noncompliance OR medication compliance OR medication non-compliance OR compliance OR adherence) AND (pharmaceutic* OR pharmaceutical preparation* OR pharmaceutical product* OR drug* OR "Pharmaceutical Preparations”[Mesh] OR pharmaceutical regime* OR regime* OR "oral therapy" OR pill* OR tablet* OR capsule OR “Immunosuppressive Agents”[Mesh] OR immunosuppressant* OR nonimmunosuppressant* OR non-immunosuppressant* OR non-immunosuppressant*)
|             |               |                                                 | (stem cell transplant* OR bone marrow transplant* OR haematopoietic stem cell transplant* OR (MH "Bone Marrow Transplantation") OR (MH "Bone Marrow Transplantation, Allogeneic") AND (MH "Compliance with Medical Regimen (Saba CCC)"") OR (MH "Compliance with Medication Regimen (Saba CCC)"") OR drug* OR “oral therapy” OR pill* OR tablet* OR capsule OR “Immunosuppressive Agents”[Mesh] OR immunosuppressant* OR nonimmunosuppressant* OR non-immunosuppressant* OR non-immunosuppressant*)
|             | #2            | MNA and risk factor                             | (1 OR pre-transplant*) AND (“Risk Factors”[Mesh] OR risk factor* OR social risk factor* OR health correlate* OR risk score* OR risk factor score* OR predictor* OR screening OR “screening tool” OR psychosocial assessment OR evaluation* OR psychosocial* OR facilitate* OR barrier*)
|             | #3            | Interventions increasing medication adherence   | #1 AND (“Psychosocial Intervention”[Mesh] OR intervention* OR psychological intervention* OR “Patient Education as Topic”[Mesh] OR “patient education” OR education OR consultation* OR counselling* OR implementation OR self-medication)
|             | #4            | Medication adherence/MNA and GvHD              | #1 AND (“Graft vs Host Disease”[Mesh] OR graft-versus-host disease* OR graft-versus-host OR graft versus host disease* OR graft-vs-host disease*)
|             | #5            | Medication adherence/MNA and infections         | #1 AND (“Infections”[Mesh] OR viral infection* OR bacterial infection* OR fungal infection* OR sepsis*)
|             | #6            | Medication adherence/MNA and hospital readmission | #1 AND (“Patient Readmission”[Mesh] OR patient readmission* OR unplanned readmission OR hospital readmission* OR rehospitalization OR intensive care unit admission* OR intensive care unit OR emergency room visit*)
|             | #7            | Medication adherence/MNA and survival           | #1 AND (“Survival”[Mesh] OR “Mortality”[Mesh] OR survival OR survivor* OR mortality OR death OR mortality rate* OR progression-free survival)
|             | #8            | Medication adherence/MNA and disease relapse   | #1 AND (“Recurrence”[Mesh] OR recurrence* OR recrudescence* OR relapse* OR disease relapse*)
| CINAHL      | #1            | Medication adherence/MNA                        | (stem cell transplant* OR bone marrow transplant* OR haematopoietic stem cell transplant* OR (MH "Bone Marrow Transplantation") OR (MH "Bone Marrow Transplantation, Allogeneic") AND (MH "Compliance with Medical Regimen (Saba CCC)"") OR (MH "Compliance with Medication Regimen (Saba CCC)"") OR drug* OR “oral therapy” OR pill* OR tablet* OR capsule OR “Immunosuppressive Agents”[Mesh] OR immunosuppressant* OR nonimmunosuppressant* OR non-immunosuppressant* OR non-immunosuppressant*)

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s).
MNA and risk factor

Interventions increasing medication adherence

Medication adherence/MNA and GvHD

Medication adherence/MNA and infections

Medication adherence/MNA and hospital readmission

Medication adherence/MNA and survival

Medication adherence/MNA and disease relapse

Medication adherence/MNA

MNA and risk factor

Interventions increasing medication adherence

Medication adherence/MNA and GvHD

Medication adherence/MNA and infections

Medication adherence/MNA and hospital readmission

Medication adherence/MNA and survival

Medication adherence/MNA and disease relapse

stem cell transplant* OR bone marrow transplant* OR haematopoietic stem cell transplant* OR hematopoietic stem cell transplant* OR allogeneic transplant* OR haploidentical transplant*) AND (medication adherence OR adherence medication OR medication nonadherence OR medication non-adherence OR medication non adherence OR Drug Adherence OR Medication Persistence OR medication non-compliance OR medication compliance OR medication non-compliance OR compliance OR adherence) AND (pharmaceutic* OR pharmaceutical preparation* OR pharmaceutical product* OR drug* OR pharmaceutical regime* OR regime* OR "oral therapy" OR pill* OR tablet* OR capsule OR Immunosuppressive Agent* OR immunosuppressant* OR non-immunosuppressant* OR non-immunosuppressant*)

Cochrane Library

Medication adherence/MNA (stem cell transplant* OR bone marrow transplant* OR haematopoietic stem cell transplant* OR hematopoietic stem cell transplant* OR allogeneic transplant* OR haploidentical transplant*) AND (medication adherence OR adherence medication OR medication nonadherence OR medication non-adherence OR medication non adherence OR Drug Adherence OR Medication Persistence OR medication non-compliance OR medication compliance OR medication non-compliance OR compliance OR adherence) AND (pharmaceutic* OR pharmaceutical preparation* OR pharmaceutical product* OR drug* OR pharmaceutical regime* OR regime* OR "oral therapy" OR pill* OR tablet* OR capsule OR Immunosuppressive Agent* OR immunosuppressant* OR non-immunosuppressant* OR non-immunosuppressant*)

PsychINFO

Medication adherence/MNA (stem cell transplant* OR bone marrow transplant* OR haematopoietic stem cell transplant* OR hematopoietic stem cell transplant* OR allogeneic transplant* OR haploidentical transplant*) AND (medication adherence OR adherence medication OR medication nonadherence OR medication non-adherence OR medication non adherence OR Drug Adherence OR Medication Persistence OR medication non-compliance OR medication compliance OR medication non-compliance OR compliance OR adherence) AND (pharmaceutic* OR pharmaceutical preparation* OR pharmaceutical product* OR drug* OR pharmaceutical regime* OR regime* OR "oral therapy" OR pill* OR tablet* OR capsule OR Immunosuppressive Agent* OR immunosuppressant* OR non-immunosuppressant* OR non-immunosuppressant*)
adherence OR adherence medication OR medication nonadherence OR medication non-adherence OR medication non adherence OR Drug Adherence OR Medication Persistence OR medication noncompliance OR medication compliance OR medication non-compliance OR medication adherence AND (pharmacetic* OR pharmaceutical preparation* OR pharmaceutical product* OR drug* OR pharmaceutical regime* OR regime* OR oral therapy OR pill* OR tablet* OR capsule OR Immunosuppressive Agent* OR immunosuppressant* OR non immunosuppressant* OR non-immunosuppressant*)

#2 MNA and risk factor
(#1 OR pre-transplant*) AND (risk factor* OR social risk factor* OR health correlate* OR risk score* OR risk factor score* OR predictor* OR screening OR screening tool OR psychosocial assessment* OR evaluation* OR psychosocial* OR facilitate* OR barrier*)

#3 Interventions increasing medication adherence
#1 AND (Psychosocial Intervention* OR intervention* OR psychological intervention* OR patient education OR education* OR consultation* OR counselling* OR implementation OR self-medication)

#4 Medication adherence/MNA and GvHD
#1 AND (Graft vs Host Disease OR graft-versus-host disease* OR graft-versus-host OR graft versus host disease* OR graft-vs-host disease*)

#5 Medication adherence/MNA and infections
#1 AND (infection* OR viral infection* OR bacterial infection* OR fungal infection* OR sepsis*)

#6 Medication adherence/MNA and hospital readmission
#1 AND (patient readmission* OR unplanned readmission* OR hospital readmission* OR rehospitalization OR intensive care unit admission* OR intensive care unit OR emergency room visit*)

#7 Medication adherence/MNA and survival
#1 AND (survival OR survivor* OR mortality OR death OR mortality rate* OR progression-free survival)

#8 Medication adherence/MNA and disease relapse
#1 AND (recurrence* OR recrudescence* OR relapse* OR disease relapse*)
<table>
<thead>
<tr>
<th>#</th>
<th>Medication adherence/MNA and disease relapse</th>
<th>#1 AND (recurrence* OR recrudescence* OR relapse* OR disease relapse*)</th>
</tr>
</thead>
<tbody>
<tr>
<td>#1</td>
<td>Medication adherence/MNA</td>
<td>&quot;stem cell transplant&quot;:ti,ab,kw OR 'bone marrow transplant':ti,ab,kw OR haematopoietic stem cell transplant&quot;:ti,ab,kw OR hematopoietic stem cell transplant&quot;:ti,ab,kw OR 'allogeneic transplant':ti,ab,kw OR 'haploidentical transplant':ti,ab,kw AND (&quot;medication adherence&quot;:ti,ab,kw OR 'medication nonadherence':ti,ab,kw OR 'medication non-adherence':ti,ab,kw OR 'medication non-adherence':ti,ab,kw OR 'medication non-adherence':ti,ab,kw OR 'drug adherence':ti,ab,kw OR 'medication non-compliance':ti,ab,kw OR 'medication compliance':ti,ab,kw OR 'medication non-compliance':ti,ab,kw OR 'medication adherence':ti,ab,kw OR 'medication non-adherence':ti,ab,kw OR 'medication non-adherence':ti,ab,kw) AND ('pharmaceutic*':ti,ab,kw OR 'pharmaceutical preparation*':ti,ab,kw OR 'pharmaceutical product*':ti,ab,kw OR drug*:ti,ab,kw OR 'pharmaceutical regime*':ti,ab,kw OR regime*:ti,ab,kw OR 'oral therapy':ti,ab,kw OR pill*:ti,ab,kw OR tablet*:ti,ab,kw OR capsule*:ti,ab,kw OR immunosuppressive agent*:ti,ab,kw OR nonimmunosuppressant*:ti,ab,kw)</td>
</tr>
<tr>
<td>#2</td>
<td>MNA and risk factor</td>
<td>&quot;risk factor*&quot;:ti,ab,kw OR 'social risk factor*':ti,ab,kw OR 'health correlate*':ti,ab,kw OR 'risk score*&quot;:ti,ab,kw OR 'risk factor score*&quot;:ti,ab,kw OR predictor*:ti,ab,kw OR screening*:ti,ab,kw OR 'screening tool&quot;:ti,ab,kw OR 'psychosocial assessment&quot;:ti,ab,kw OR evaluation*:ti,ab,kw OR psychosocial&quot;:ti,ab,kw OR facilitate*:ti,ab,kw OR barrier*:ti,ab,kw AND ('pre transplant&quot;:ti,ab,kw OR 'stem cell transplant&quot;:ti,ab,kw OR 'bone marrow transplant&quot;:ti,ab,kw OR 'stem cell transplant&quot;:ti,ab,kw OR 'bone marrow transplant&quot;:ti,ab,kw OR 'haematopoietic stem cell transplant&quot;:ti,ab,kw OR hematopoietic stem cell transplant&quot;:ti,ab,kw OR 'allogeneic transplant&quot;:ti,ab,kw OR 'haploidentical transplant&quot;:ti,ab,kw) AND (&quot;medication adherence&quot;:ti,ab,kw OR 'medication nonadherence':ti,ab,kw OR 'medication non- adherence':ti,ab,kw OR 'medication non-adherence':ti,ab,kw OR 'drug adherence':ti,ab,kw OR 'medication non-compliance':ti,ab,kw OR 'medication compliance':ti,ab,kw OR 'medication non-compliance':ti,ab,kw OR 'medication non-adherence':ti,ab,kw OR 'medication non-adherence':ti,ab,kw OR 'medication non-adherence':ti,ab,kw OR 'drug adherence':ti,ab,kw OR 'medication non-compliance':ti,ab,kw OR 'medication compliance':ti,ab,kw OR 'medication non-compliance':ti,ab,kw OR 'medication non-adherence':ti,ab,kw OR 'medication non-adherence':ti,ab,kw) AND (&quot;pharmaceutic&quot;:ti,ab,kw OR 'pharmaceutical preparation&quot;:ti,ab,kw OR 'pharmaceutical product&quot;:ti,ab,kw OR drug&quot;:ti,ab,kw OR 'pharmaceutical regime&quot;:ti,ab,kw OR regime&quot;:ti,ab,kw OR 'oral therapy&quot;:ti,ab,kw OR pill&quot;:ti,ab,kw OR tablet&quot;:ti,ab,kw OR capsule&quot;:ti,ab,kw OR immunosuppressive agent&quot;:ti,ab,kw OR nonimmunosuppressant&quot;:ti,ab,kw)</td>
</tr>
<tr>
<td>#3</td>
<td>Interventions increasing medication adherence</td>
<td>&quot;psychosocial intervention&quot;:ti,ab,kw OR intervention&quot;:ti,ab,kw OR 'psychological intervention&quot;:ti,ab,kw OR 'patient education&quot;:ti,ab,kw OR education&quot;:ti,ab,kw OR consultation&quot;:ti,ab,kw OR counselling&quot;:ti,ab,kw OR implementation&quot;:ti,ab,kw OR 'self medication&quot;:ti,ab,kw AND ('stem cell transplant&quot;:ti,ab,kw OR 'bone marrow transplant&quot;:ti,ab,kw OR 'stem cell transplant&quot;:ti,ab,kw OR 'bone marrow transplant&quot;:ti,ab,kw OR haematopoietic stem cell transplant&quot;:ti,ab,kw OR hematopoietic stem cell transplant&quot;:ti,ab,kw OR 'allogeneic transplant&quot;:ti,ab,kw OR 'haploidentical transplant&quot;:ti,ab,kw) AND (&quot;medication adherence&quot;:ti,ab,kw OR 'medication nonadherence':ti,ab,kw OR 'medication non- adherence':ti,ab,kw OR 'medication non-adherence':ti,ab,kw OR 'medication non-adherence':ti,ab,kw OR 'drug adherence':ti,ab,kw OR 'medication non-compliance':ti,ab,kw OR 'medication compliance':ti,ab,kw OR 'medication non-compliance':ti,ab,kw OR 'medication non-adherence':ti,ab,kw OR 'medication non-adherence':ti,ab,kw) AND (&quot;pharmaceutic&quot;:ti,ab,kw OR 'pharmaceutical preparation&quot;:ti,ab,kw OR 'pharmaceutical product&quot;:ti,ab,kw OR drug&quot;:ti,ab,kw OR 'pharmaceutical regime&quot;:ti,ab,kw OR regime&quot;:ti,ab,kw OR 'oral therapy&quot;:ti,ab,kw OR pill&quot;:ti,ab,kw OR tablet&quot;:ti,ab,kw OR capsule&quot;:ti,ab,kw OR immunosuppressive agent&quot;:ti,ab,kw OR nonimmunosuppressant&quot;:ti,ab,kw)</td>
</tr>
<tr>
<td>#4</td>
<td>Medication adherence/MNA and GvHD</td>
<td>&quot;stem cell&quot;:ti,exp OR &quot;stem cell&quot; OR &quot;bone marrow&quot;:ti,exp OR &quot;bone marrow&quot; OR &quot;stem cell&quot;:ti,exp OR &quot;stem cell&quot; OR &quot;bone marrow&quot;:ti,exp OR &quot;bone marrow&quot; AND transplant* OR 'haploidentical stem cell':ti,exp OR 'hematopoietic stem cell':ti,exp OR 'haematopoietic stem cell' OR (haematopoietic AND移植) OR 'bone marrow':ti,exp OR 'bone marrow' OR (&quot;bone marrow&quot;:ti,exp OR &quot;bone marrow&quot;) OR (&quot;stem cell&quot;:ti,exp OR &quot;stem cell&quot;) OR &quot;bone marrow&quot;:ti,exp OR &quot;bone marrow&quot; OR (&quot;stem cell&quot;:ti,exp OR &quot;stem cell&quot;) OR &quot;bone marrow&quot;:ti,exp OR &quot;bone marrow&quot; AND transplant* OR 'haploidentical stem cell':ti,exp OR 'hematopoietic stem cell':ti,exp OR 'haematopoietic stem cell' OR (haematopoietic AND ...)</td>
</tr>
</tbody>
</table>
Medication adherence/MNA and hospital readmission

(Medication adherence/MNA and hospital readmission) AND (stem cell transplant* OR bone marrow transplant* OR haematopoietic stem cell transplant* OR hematopoietic stem cell transplant* OR allogeneic transplant* OR haploidentical transplant* OR 'bone marrow' OR 'bone marrow' OR 'stem cell' OR 'stem cell' OR 'haematopoietic stem cell' OR (haematopoietic AND stem* OR 'stem cell') OR transplantation* OR transplantation*) AND (patient readmission* OR unplanned readmission* OR hospital readmission* OR rehospitalization OR intensive care unit admission* OR intensive care unit admission* OR 'emergency room visit') AND (survival OR survivor OR mortality OR death OR 'mortality rate' OR 'progression-free survival') AND (oral therapy OR pill OR tablet OR capsule OR 'immunosuppressive agent' OR 'immunosuppressant' OR 'non immunosuppressant') AND (oral therapy OR pill OR tablet OR capsule OR 'immunosuppressive agent' OR 'immunosuppressant' OR 'non immunosuppressant')

Medication adherence/MNA and survival

(Medication adherence/MNA and survival) AND (stem cell transplant* OR bone marrow transplant* OR haematopoietic stem cell transplant* OR hematopoietic stem cell transplant* OR allogeneic transplant* OR haploidentical transplant* OR 'bone marrow' OR 'bone marrow' OR 'stem cell' OR 'stem cell' OR 'haematopoietic stem cell' OR (haematopoietic AND stem* OR 'stem cell') OR transplantation* OR transplantation*) AND (oral therapy OR pill OR tablet OR capsule OR 'immunosuppressive agent' OR 'immunosuppressant' OR 'non immunosuppressant') AND (oral therapy OR pill OR tablet OR capsule OR 'immunosuppressive agent' OR 'immunosuppressant' OR 'non immunosuppressant')

Medication adherence/MNA and disease relapse

(Medication adherence/MNA and disease relapse) AND (stem cell transplant* OR bone marrow transplant* OR haematopoietic stem cell transplant* OR hematopoietic stem cell transplant* OR allogeneic transplant* OR haploidentical transplant* OR 'stem cell' OR 'stem cell' OR 'haematopoietic stem cell' OR (haematopoietic AND 'stem cell') OR transplantation* OR transplantation*) AND (oral therapy OR pill OR tablet OR capsule OR 'immunosuppressive agent' OR 'immunosuppressant' OR 'non immunosuppressant') AND (oral therapy OR pill OR tablet OR capsule OR 'immunosuppressive agent' OR 'immunosuppressant' OR 'non immunosuppressant')

GvHD, Graft-versus-Host Disease; MNA, medication non-adherence.